Enanta Pharmaceuticals (ENTA) News Today $11.01 -0.37 (-3.25%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$11.02 +0.01 (+0.05%) As of 10/17/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ENTA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Enanta’s Zelicapavir Shows Positive Phase 2b Results for RSV in High-Risk AdultsOctober 16 at 4:51 PM | msn.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 10, 2025 | marketbeat.comEnanta Pharmaceuticals' (ENTA) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 9, 2025 | marketbeat.comEnanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesOctober 3, 2025 | tmcnet.comEnanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesOctober 2, 2025 | finance.yahoo.comFY2027 Earnings Estimate for ENTA Issued By Leerink PartnrsOctober 2, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Rating Increased to Buy at Jefferies Financial GroupOctober 1, 2025 | marketbeat.comCal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionOctober 1, 2025 | benzinga.comEnanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockSeptember 30, 2025 | businesswire.comEnanta's RSV treatment helps speed up recovery in study, shares surgeSeptember 30, 2025 | msn.comEnanta Pharmaceuticals stock falls after announcing $50 million offeringSeptember 30, 2025 | za.investing.comWestPark Capital Maintains Enanta Pharmaceuticals (ENTA) Buy RecommendationSeptember 30, 2025 | msn.comEnanta Pharmaceuticals Announces Proposed Public Offering of Common StockSeptember 30, 2025 | businesswire.comEnanta Pharmaceuticals (NASDAQ:ENTA) Price Target Raised to $28.00September 30, 2025 | marketbeat.comEnanta stock tumbles after RSV drug misses primary endpointSeptember 29, 2025 | za.investing.comEnanta's RSV treatment misses main goal in mid-stage studySeptember 29, 2025 | msn.comEnanta shares rise despite RSV trial failing to meet main goalSeptember 29, 2025 | msn.comEnanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk AdultsSeptember 29, 2025 | finance.yahoo.comEnanta Pharmaceuticals Stock Rises 58% – Here’s An Important UpdateSeptember 29, 2025 | msn.comEnanta Pharmaceuticals, Inc. - Special CallSeptember 29, 2025 | seekingalpha.comEnanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design ChangeSeptember 29, 2025 | seekingalpha.comEnanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk AdultsSeptember 29, 2025 | benzinga.comEnanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk AdultsSeptember 29, 2025 | businesswire.comEnanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk AdultsSeptember 26, 2025 | businesswire.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Buy" from AnalystsSeptember 16, 2025 | marketbeat.comEvercore ISI Cuts Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $12.00September 16, 2025 | marketbeat.comIeq Capital LLC Makes New $232,000 Investment in Enanta Pharmaceuticals, Inc. $ENTASeptember 9, 2025 | marketbeat.comTrexquant Investment LP Has $1.60 Million Stake in Enanta Pharmaceuticals, Inc. $ENTASeptember 8, 2025 | marketbeat.comNuveen LLC Makes New Investment in Enanta Pharmaceuticals, Inc. $ENTASeptember 8, 2025 | marketbeat.comPDT Partners LLC Grows Stake in Enanta Pharmaceuticals, Inc. $ENTASeptember 7, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Analysts at Westpark CapitalSeptember 4, 2025 | marketbeat.comEnanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.September 3, 2025 | businesswire.comEnanta Pharmaceuticals, Inc. $ENTA Shares Bought by Stonepine Capital Management LLCAugust 26, 2025 | marketbeat.comEnanta Pharmaceuticals to Participate in September Investor ConferencesAugust 21, 2025 | finance.yahoo.comEnanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European UnionAugust 20, 2025 | uk.finance.yahoo.comHC Wainwright Has Positive Outlook of ENTA FY2025 EarningsAugust 16, 2025 | marketbeat.comResearch Analysts Set Expectations for ENTA FY2025 EarningsAugust 16, 2025 | marketbeat.comEnanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” SeriesAugust 14, 2025 | theglobeandmail.comEnanta Pharmaceuticals (NASDAQ:ENTA) Given New $25.00 Price Target at JMP SecuritiesAugust 13, 2025 | marketbeat.comEnanta price target raised to $25 from $24 at Citizens JMPAugust 13, 2025 | msn.comEnanta Pharmaceuticals (NASDAQ:ENTA) Issues Earnings ResultsAugust 12, 2025 | marketbeat.comEnanta Pharmaceuticals: Fiscal Q3 Earnings SnapshotAugust 11, 2025 | sfgate.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025August 11, 2025 | businesswire.comQ3 Earnings Estimate for ENTA Issued By HC WainwrightJuly 31, 2025 | marketbeat.comEnanta Pharmaceuticals' (ENTA) Buy Rating Reaffirmed at HC WainwrightJuly 28, 2025 | marketbeat.comEnanta Pharmaceuticals (ENTA) Projected to Post Earnings on MondayJuly 28, 2025 | marketbeat.comOne Enanta Pharmaceuticals Insider Raised Their Stake In The Previous YearJuly 26, 2025 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by BrokeragesJuly 23, 2025 | marketbeat.comEnanta Pharmaceuticals to Participate in Baird’s Biotech Discovery SeriesJuly 16, 2025 | finance.yahoo.comEnanta Pharmaceuticals to Participate in Baird's Biotech Discovery SeriesJuly 15, 2025 | businesswire.com Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTA Media Mentions By Week ENTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTA News Sentiment▼1.230.46▲Average Medical News Sentiment ENTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTA Articles This Week▼13▲ENTA Articles Average Week Get the Latest News and Ratings for ENTA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Enanta Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PGEN News Today XNCR News Today OCS News Today ORKA News Today BGM News Today MNMD News Today VALN News Today PROK News Today ANAB News Today KURA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTA) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
